# US 2021/0261948 A1 · mRNA display antibody library and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261948 A1
- Document ID: US20210261948A1
- Status: Published application
- Kind: A1
- Application number: 17/316,381
- Filed: 2021-05-10
- Published: 2021-08-26
- Earliest claimed: 2017-11-20
- Assignees: NantBio, Inc.
- Applicants: NantBio, Inc.
- Inventors: Clifford Anders Olson; Kayvan Niazi
- Web page: https://patentgrep.com/patent/US20210261948A1

## CPC

- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/1062: {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- C12N 15/86: Viral vectors
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C40B 40/10: Libraries containing peptides or polypeptides, or derivatives thereof
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions, methods and uses of a recombinant virus and/or recombinant viral vector encoding a distinct antibody or antibody fragment generated from high-diversity nucleic acid library are presented. Preferably, the recombinant virus is genetically modified, low immunogenic virus, for example, an E2b-deleted adenovirus. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method of generating a recombinant antibody, comprising:
generating or providing (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, wherein each of the sub-libraries (1)-(3) comprises a plurality of members;
wherein each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions;
recombining at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library to form an expression library member in an expression library, wherein the expression library comprises a plurality of expression library members, each expression library member encoding a distinct antibody or antibody fragment; and
generating a recombinant viral vector comprising at least one expression library member.

### Claim 14 (depends on 13)

The method of claim 13, wherein the recombinant viral vector is derived from a genetically modified, low immunogenic virus.

### Claim 15 (depends on 14)

The method of claim 14, wherein the genetically modified, low immunogenic virus is a human adenovirus serotype 5 with a mutation in at least one of the following genes: E1A, E1B, E2B, E3.

### Claim 16 (depends on 13)

The method of claim 13, wherein the recombinant viral vector further comprises a nucleic acid fragment encoding a signaling peptide facilitating a secretion of the distinct antibody or antibody fragment.

### Claim 17 (depends on 13)

The method of claim 13, wherein the random cassette is generated using an oligonucleotide selected from SEQ ID NO:1-SEQ ID NO:25.

### Claim 18 (depends on 13)

The method of claim 13, further comprising a step of contacting a recombinant virus having the recombinant viral vector with a mammalian cell.

### Claim 19 (depends on 18)

The method of claim 18, wherein the contacting comprises administering the recombinant virus to a mammal.

### Claim 20 (depends on 18)

The method of claim 18, wherein the mammalian cell is an autologous cell of a patient having a tumor, and wherein the contacting comprises co-incubating the autologous cell with the mammalian cell ex vivo.
